IL151376A0 - Malonamic acids and derivatives thereof as thyroid receptor ligands - Google Patents

Malonamic acids and derivatives thereof as thyroid receptor ligands

Info

Publication number: IL151376A0
Authority: IL; Israel
Prior art keywords: derivatives; receptor ligands; thyroid receptor; malonamic acids; malonamic
Prior art date: 2000-03-31

Application number

IL15137601A

Other languages

English (en)

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-31

Filing date

2001-03-07

Publication date

2003-04-10

2001-03-07 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-04-10 Publication of IL151376A0 publication Critical patent/IL151376A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL15137601A 2000-03-31 2001-03-07 Malonamic acids and derivatives thereof as thyroid receptor ligands IL151376A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19361800P	2000-03-31	2000-03-31
PCT/IB2001/000317 WO2001072692A1 (en)	2000-03-31	2001-03-07	Malonamic acids and derivatives thereof as thyroid receptor ligands

Publications (1)

Publication Number	Publication Date
IL151376A0 true IL151376A0 (en)	2003-04-10

Family

ID=22714346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15137601A IL151376A0 (en)	2000-03-31	2001-03-07	Malonamic acids and derivatives thereof as thyroid receptor ligands

Country Status (38)

Country	Link
US (1)	US20070173548A1 (es)
EP (1)	EP1268404B1 (es)
JP (1)	JP3866977B2 (es)
KR (1)	KR20020089420A (es)
CN (1)	CN1422246A (es)
AP (1)	AP2002002634A0 (es)
AR (1)	AR033516A1 (es)
AT (1)	ATE382602T1 (es)
AU (1)	AU2001237665A1 (es)
BG (1)	BG107036A (es)
BR (1)	BR0109625A (es)
CA (1)	CA2403902C (es)
CR (1)	CR6742A (es)
CZ (1)	CZ20023190A3 (es)
DE (1)	DE60132181D1 (es)
DZ (1)	DZ3276A1 (es)
EA (1)	EA200200921A1 (es)
EE (1)	EE200200566A (es)
GT (1)	GT200100041A (es)
HK (1)	HK1052498A1 (es)
HU (1)	HUP0300329A3 (es)
IL (1)	IL151376A0 (es)
IS (1)	IS6516A (es)
MA (1)	MA26886A1 (es)
MX (1)	MXPA02009702A (es)
NO (1)	NO20024639L (es)
NZ (1)	NZ520660A (es)
OA (1)	OA12237A (es)
PA (1)	PA8513801A1 (es)
PE (1)	PE20011186A1 (es)
PL (1)	PL358596A1 (es)
SK (1)	SK13762002A3 (es)
SV (1)	SV2002000357A (es)
TN (1)	TNSN01048A1 (es)
TR (1)	TR200202249T2 (es)
WO (1)	WO2001072692A1 (es)
YU (1)	YU74102A (es)
ZA (1)	ZA200207444B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6790978B2 (en)	1999-03-29	2004-09-14	Novartis Ag	Thyromimetic organic compounds
US6599942B1 (en)	1999-03-29	2003-07-29	Novartis Ag	Thyromimetic organic compounds
DK1257526T3 (da) *	2000-02-17	2005-09-12	Bristol Myers Squibb Co	Anilin-afledte ligander til thyreoidea-receptoren
WO2002051805A1 (de) *	2000-12-27	2002-07-04	Bayer Aktiengesellschaft	Indol-derivate
GB2374009A (en) *	2001-02-12	2002-10-09	Novartis Ag	Method of treating hair loss
CA2449515A1 (en) *	2001-08-24	2003-03-06	Karo Bio Ab	Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
US6806381B2 (en)	2001-11-02	2004-10-19	Bristol-Myers Squibb Company	Process for the preparation of aniline-derived thyroid receptor ligands
TW200504021A (en)	2003-01-24	2005-02-01	Bristol Myers Squibb Co	Substituted anilide ligands for the thyroid receptor
CA2546601A1 (en)	2003-11-19	2005-06-09	Metabasis Therapeutics, Inc.	Novel phosphorus-containing thyromimetics
US20090232879A1 (en)	2005-05-26	2009-09-17	Metabasis Therapeutics, Inc.	Thyromimetics for the Treatment of Fatty Liver Diseases
GB0606201D0 (en) *	2006-03-28	2006-05-10	Karobio Ab	Improved crytalline material
JP2010500300A (ja)	2006-08-08	2010-01-07	サノフィ−アベンティス	アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
US8633245B2 (en) *	2008-04-11	2014-01-21	Institute Of Medicinal Molecular Design, Inc.	PAI-1 inhibitor
RU2010145916A (ru) *	2008-04-11	2012-05-20	Инститьют Оф Медисинал Молекьюлар Дизайн, Инк. (Jp)	Ингибитор pai-1
WO2010003624A2 (en)	2008-07-09	2010-01-14	Sanofi-Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
CN102197019A (zh)	2008-10-27	2011-09-21	卡迪拉保健有限公司	甲状腺受体配体
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010086878A2 (en)	2009-01-09	2010-08-05	Cadila Healthcare Limited	Thyroid receptor modulators
KR20120060207A (ko)	2009-08-26	2012-06-11	사노피	신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
WO2012120055A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de)	2011-03-08	2014-12-24	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en)	2011-03-08	2014-09-09	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120057A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2695611B1 (en)	2012-08-06	2014-10-01	Dr. August Wolff GmbH & Co. KG Arzneimittel	Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
WO2015156302A1 (ja) *	2014-04-09	2015-10-15	ゴールドクレスト医薬研究所株式会社	皮膚症状の改善剤、育毛剤又はスリミング剤
BR112019010249A2 (pt)	2016-11-21	2019-09-10	Viking Therapeutics Inc	método de tratamento de doença de armazenamento de glicogênio
US11707472B2 (en)	2017-06-05	2023-07-25	Viking Therapeutics, Inc.	Compositions for the treatment of fibrosis
CN107474007B (zh) *	2017-08-28	2019-04-19	上海再启生物技术有限公司	一种制备3，6-二羟基苯二甲酰亚胺的方法
US11787828B2 (en)	2018-03-22	2023-10-17	Viking Therapeutics, Inc.	Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en)	2018-12-05	2020-06-11	Viking Therapeutics, Inc.	Compositions for the treatment of fibrosis and inflammation
CN112300133B (zh) *	2019-07-31	2024-07-30	深圳微芯生物科技股份有限公司	一种杂环化合物及其应用
EP3878837A1 (en) *	2020-03-11	2021-09-15	OM Pharma SA	2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4069343A (en) *	1973-03-23	1978-01-17	American Home Products Corporation	Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4554290A (en) *	1983-06-17	1985-11-19	Ciba-Geigy Corporation	Oxamic acid derivatives
US5061798A (en) *	1985-01-18	1991-10-29	Smith Kline & French Laboratories, Ltd.	Benzyl pyridyl and pyridazinyl compounds
GB8501372D0 (en) *	1985-01-18	1985-02-20	Smith Kline French Lab	Chemical compounds
US5232947A (en) *	1988-07-04	1993-08-03	Meiji Seika Kaisha, Ltd.	Oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
US5284971A (en) *	1992-07-16	1994-02-08	Syntex (U.S.A.) Inc.	4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
DK0580550T3 (da) *	1992-07-21	1998-02-02	Ciba Geigy Ag	Oxamidsyrederivater som hypercholesterolæmiske midler
CO5160290A1 (es) *	1999-03-29	2002-05-30	Novartis Ag	Derivados de acido fenoxifeniloxamico sustituido .
AR018698A1 (es) *	1999-06-01	2001-11-28	Procter & Gamble	Metodo para el tratamiento de la perdida del cabello el cual comprende administrar una composicion que comprende un compuesto el cual no afecta al corazon
US6664291B2 (en) *	2000-03-31	2003-12-16	Pfizer, Inc.	Malonamic acids and derivatives thereof as thyroid receptor ligands

2001
- 2001-03-07 HK HK03104860.6A patent/HK1052498A1/zh unknown
- 2001-03-07 KR KR1020027013044A patent/KR20020089420A/ko not_active Ceased
- 2001-03-07 SK SK1376-2002A patent/SK13762002A3/sk not_active Application Discontinuation
- 2001-03-07 PL PL01358596A patent/PL358596A1/xx not_active Application Discontinuation
- 2001-03-07 IL IL15137601A patent/IL151376A0/xx unknown
- 2001-03-07 MX MXPA02009702A patent/MXPA02009702A/es active IP Right Grant
- 2001-03-07 AT AT01910082T patent/ATE382602T1/de not_active IP Right Cessation
- 2001-03-07 CA CA002403902A patent/CA2403902C/en not_active Expired - Fee Related
- 2001-03-07 EE EEP200200566A patent/EE200200566A/xx unknown
- 2001-03-07 HU HU0300329A patent/HUP0300329A3/hu unknown
- 2001-03-07 DZ DZ013276A patent/DZ3276A1/fr active
- 2001-03-07 DE DE60132181T patent/DE60132181D1/de not_active Expired - Lifetime
- 2001-03-07 EP EP01910082A patent/EP1268404B1/en not_active Expired - Lifetime
- 2001-03-07 CN CN01807559A patent/CN1422246A/zh active Pending
- 2001-03-07 BR BR0109625-7A patent/BR0109625A/pt not_active IP Right Cessation
- 2001-03-07 JP JP2001570607A patent/JP3866977B2/ja not_active Expired - Fee Related
- 2001-03-07 CZ CZ20023190A patent/CZ20023190A3/cs unknown
- 2001-03-07 TR TR2002/02249T patent/TR200202249T2/xx unknown
- 2001-03-07 AU AU2001237665A patent/AU2001237665A1/en not_active Abandoned
- 2001-03-07 YU YU74102A patent/YU74102A/sh unknown
- 2001-03-07 EA EA200200921A patent/EA200200921A1/ru unknown
- 2001-03-07 NZ NZ520660A patent/NZ520660A/en not_active Application Discontinuation
- 2001-03-07 WO PCT/IB2001/000317 patent/WO2001072692A1/en not_active Ceased
- 2001-03-07 AP APAP/P/2002/002634A patent/AP2002002634A0/en unknown
- 2001-03-07 OA OA1200200299A patent/OA12237A/en unknown
- 2001-03-16 PA PA20018513801A patent/PA8513801A1/es unknown
- 2001-03-19 GT GT200100041A patent/GT200100041A/es unknown
- 2001-03-28 PE PE2001000290A patent/PE20011186A1/es not_active Application Discontinuation
- 2001-03-29 AR ARP010101509A patent/AR033516A1/es unknown
- 2001-03-30 TN TNTNSN01048A patent/TNSN01048A1/fr unknown
- 2001-03-30 SV SV2001000357A patent/SV2002000357A/es not_active Application Discontinuation
2002
- 2002-08-21 IS IS6516A patent/IS6516A/is unknown
- 2002-08-26 BG BG107036A patent/BG107036A/bg unknown
- 2002-08-28 CR CR6742A patent/CR6742A/es not_active Application Discontinuation
- 2002-09-17 ZA ZA200207444A patent/ZA200207444B/en unknown
- 2002-09-24 MA MA26837A patent/MA26886A1/fr unknown
- 2002-09-27 NO NO20024639A patent/NO20024639L/no not_active Application Discontinuation
2007
- 2007-03-07 US US11/715,035 patent/US20070173548A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE382602T1 (de)	2008-01-15
OA12237A (en)	2003-10-23
AR033516A1 (es)	2003-12-26
US20070173548A1 (en)	2007-07-26
SK13762002A3 (sk)	2004-01-08
CA2403902C (en)	2007-04-24
EA200200921A1 (ru)	2003-02-27
SV2002000357A (es)	2002-07-16
KR20020089420A (ko)	2002-11-29
TR200202249T2 (tr)	2003-01-21
IS6516A (is)	2002-08-21
PE20011186A1 (es)	2001-11-15
AU2001237665A1 (en)	2001-10-08
BR0109625A (pt)	2003-04-22
EP1268404A1 (en)	2003-01-02
PL358596A1 (en)	2004-08-09
HUP0300329A3 (en)	2004-08-30
NO20024639D0 (no)	2002-09-27
MXPA02009702A (es)	2003-03-27
YU74102A (sh)	2006-03-03
DE60132181D1 (de)	2008-02-14
MA26886A1 (fr)	2004-12-20
JP2003528847A (ja)	2003-09-30
HK1052498A1 (zh)	2003-09-19
WO2001072692A1 (en)	2001-10-04
TNSN01048A1 (fr)	2005-11-10
BG107036A (bg)	2003-04-30
HUP0300329A2 (hu)	2003-07-28
PA8513801A1 (es)	2002-02-21
JP3866977B2 (ja)	2007-01-10
CZ20023190A3 (cs)	2003-10-15
AP2002002634A0 (en)	2002-09-30
NZ520660A (en)	2004-03-26
DZ3276A1 (fr)	2001-10-04
EE200200566A (et)	2004-06-15
NO20024639L (no)	2002-09-27
GT200100041A (es)	2002-03-22
CR6742A (es)	2003-11-25
CN1422246A (zh)	2003-06-04
CA2403902A1 (en)	2001-10-04
EP1268404B1 (en)	2008-01-02
ZA200207444B (en)	2003-09-17

Publication	Publication Date	Title
IL151376A0 (en)	2003-04-10	Malonamic acids and derivatives thereof as thyroid receptor ligands
IL144765A0 (en)	2002-06-30	Oxamic acids and derivatives as thyroid receptor ligands
PL366149A1 (en)	2005-01-24	Aniline-derived ligands for the thyroid receptor
GB2366474B (en)	2005-02-16	Geophones
GB0016787D0 (en)	2000-08-30	Compounds useful in therapy
IL152581A0 (en)	2003-05-29	Phenylglycine derivatives
HUP0100870A3 (en)	2002-11-28	Alpha-aminoamide derivatives useful as analgesic agents
EP1274424A4 (en)	2003-09-17	CONNECTIONS AND PROCEDURE
AU5073101A (en)	2001-11-07	Lipid composition and use thereof
IL153539A0 (en)	2003-07-06	Protein complexes and methods for the preparation thereof
GB0020616D0 (en)	2000-10-11	Particulates
IL155998A0 (en)	2003-12-23	Benzyl (idene) -lactams and their use as 5ht1-receptor ligands
GB0018968D0 (en)	2000-09-20	Particulate composition
GB2358492B (en)	2004-07-07	Software debugging
GB2369569B (en)	2002-10-23	Childs duvet
HUP0102960A3 (en)	2002-05-28	Injection-type anchor
GB9929801D0 (en)	2000-02-09	Anti-cancer agents iii
EP1321151A4 (en)	2009-07-15	MEANS FOR THE TREATMENT OF PARKINSON
GB2348804B (en)	2001-03-14	Pillows
AU3402001A (en)	2001-08-07	Novel ligands and methods for preparing same
GB0018504D0 (en)	2000-09-13	Antipyretic composition
GB0014046D0 (en)	2000-08-02	Compounds useful in therapy
GB0028293D0 (en)	2001-01-03	Releasable ligand
PL356210A1 (en)	2004-06-14	Glyburide composition
GB9926422D0 (en)	2000-01-12	Particulate snow-sport surface